Please assess the completion status of the following clinical trial:

Trial Title: To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 19 and 55 years, both inclusive~* Body Mass Index (BMI) between 18.0 and 29.9 kg/m2 (both inclusive) and a body weight ≥ 50 kg~Exclusion Criteria:~* Subject is a female.~* Clinically significant allergic reactions, hypersensitivity~* A disease classed as significant by the Investigator~* Non-healing wound, ulcer, bone fracture, a major surgical procedure, significant traumatic injury~* Any malignancy~* Undergone treatment with an investigational drug or participated in another clinical trial~* Plans to father a child or donates sperms

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P16 (Type: EXPERIMENTAL): CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
- EU-approved Avastin (Type: ACTIVE_COMPARATOR): EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
- US-licensed Avastin (Type: ACTIVE_COMPARATOR): US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).